Monthly Archives: November 2023

Cardiovascular

Obesity drug “effective treatment” to reduce cardiovascular events in overweight adults, experts flag

Posted on by yun
13
Nov

14 Nov 2023 — An international clinical trial found that semaglutide therapy lowered cardiovascular events by 20% in overweight or obese adults who don’t have diabetes. This effect was on top of evidence-based care for cardiovascular disease the patients received in the trial. While therapies are limited for obesity and overweight, the researchers note the […]

Continue reading →
Congenital disorders

Global Opioid Use Disorder (OUD) Market Size To Grow USD 7.8 Billion by 2032

Posted on by yun

New York, United States, Nov. 14, 2023 (GLOBE NEWSWIRE) — The Global Opioid Use Disorder (OUD) Market Size is To Grow from USD 2.8 Billion in 2022 to USD 7.8 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 10.7% during the forecast period. Get a Sample PDF Brochure https://www.sphericalinsights.com/request-sample/2364   Opioids are synthesized in […]

Continue reading →
Congenital disorders

Global Patient Handling Equipment Market Size To Grow USD 18.9 Billion By 2032

Posted on by yun

New York, United States, Nov. 14, 2023 (GLOBE NEWSWIRE) — Global Patient Handling Equipment Market Size is To Grow from USD 10.4 Billion in 2022 to USD 18.9 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period.                          […]

Continue reading →
Congenital disorders

Developmental and foliation changes due to dysregulation of adenosine kinase in the cerebellum

Posted on by yun
13
Nov

Abstract Adenosine kinase (ADK), the major adenosine-metabolizing enzyme, plays a key role in brain development and disease. In humans, mutations in the Adk gene have been linked to developmental delay, stunted growth, and intellectual disability. To better understand the role of ADK in brain development, it is important to dissect the specific roles of the […]

Continue reading →
Cancer and neoplasms

MiR-200b categorizes patients into pancreas cystic lesion subgroups with different malignant potential

Posted on by yun
13
Nov

Abstract Extracellular vesicles (EV) carry their cargo in a membrane protected form, however, their value in early diagnostics is not well known. Although pancreatic cysts are heterogeneous, they can be clustered into the larger groups of pseudocysts (PC), and serous and mucinous pancreatic cystic neoplasms (S-PCN and M-PCN, respectively). In contrast to PCs and S-PCNs, […]

Continue reading →
Blood

Red Cross looking for some good Buddies with ‘Elf’-inspired blood drive

Posted on by yun
13
Nov

(Photo Illustration/MetroCreative) PARKERSBURG — The American Red Cross is encouraging people to add a new tradition to their holiday repertoire — donating blood. To celebrate the 20th anniversary of the release of the classic Christmas movie “Elf,” people who donate blood through Nov. 30 will receive a pair of “Elf” and Red Cross socks, while […]

Continue reading →
Cancer and neoplasms

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

Posted on by yun

New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof of concept endpoints BASEL, Switzerland – 14th November 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines […]

Continue reading →
Infection

OTC Artificial Tears Infections: Risks for Patients, Clinicians

Posted on by yun

The Food and Drug Administration (FDA) has recalled dozens of over-the-counter eye drops — artificial tears — in 2023 due to contamination and unsafe manufacturing practices. Four deaths from sepsis, 14 cases of vision loss and more than 80 infections were reported as of May. Most of the patients reported using EzriCare Artificial Tears, which […]

Continue reading →
Congenital disorders

FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura

Posted on by yun
13
Nov

MONDAY, Nov. 13, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Adzynma, the first recombinant protein product indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). Adzynma is a purified recombinant form of the ADAMTS13 enzyme that enhances the low […]

Continue reading →
Infection

Understanding the Long-Term Implications of Mild Infections and the Role of Vaccination

Posted on by yun
13
Nov

Frequently Asked Questions (FAQ): 1. What is long COVID?Long COVID refers to the persistence of symptoms experienced by individuals even after recovering from an initial COVID-19 infection. These lingering symptoms can last for several weeks or months. 2. Can mild infections lead to long COVID?According to the Centers for Disease Control and Prevention (CDC), even […]

Continue reading →